Direct antiviral treatment of chronic hepatitis C in heart transplant recipients. Issue 1 (21st December 2017)

• Record Type: Journal Article
• Authors: Vitrone, Martina; Andini, Roberto; Mattucci, Irene; Maiello, Ciro; Atripaldi, Luigi; Durante‐Mangoni, Emanuele; Zampino, Rosa
• Is Part Of: Transplant infectious disease. Volume 20:Issue 1(2018)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2017-12-21
• Subjects: chronic hepatitis C -- direct‐acting antiviral agents (DAAs) -- heart transplant -- sustained virological response (SVR); Transplantation of organs, tissues, etc -- Complications -- Periodicals; Communicable diseases -- Periodicals; Infection -- Periodicals; 617.01
• DOI: 10.1111/tid.12813
• Languages: English
• ISSNs: 1398-2273

Abstract

Abstract: Direct‐acting antiviral agents (DAAs) are a safe and effective treatment for chronic hepatitis C (CHC). This may be particularly valuable for patients with severe comorbidities or baseline conditions, including non‐liver solid organ transplant. We report cases of two heart transplant recipients with CHC treated with DAAs (sofosbuvir and daclatasvir) achieving sustained virological response. Treatment was well tolerated and no relevant side effects were observed. The drug‐drug interactions and graft function were carefully monitored.